Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 1, 2008 Brian Orelli	WuXi and Covance Call It Quits WuXi PharmaTech and Covance broke up yesterday - just three months after announcing they'd form an alliance to perform pre-clinical research for drug developers looking for research and development on the cheap.
The Motley Fool August 13, 2009 Brian Orelli	WuXi: Making Money Both Ways Cost-cutting and revenue growth make pharma outsourcing specialist WuXi a looker for the year.
The Motley Fool March 14, 2008 Brian Orelli	No Slowdown for China's WuXi Chinese drug researcher and manufacturer WuXi signs more drug development deals and buys a U.S. manufacturing services company.
The Motley Fool November 12, 2009 Brian Orelli	How Do You Say 'Drug Development' in Mandarin? Drug giant Novartis announces that it's heading to China in a big way.
The Motley Fool May 30, 2008 Brian Orelli	WuXi Woos Pharma Pharmaceutical outsourcing specialist WuXi PharmaTech proves that outsourcing to China isn't dead yet and neither are Chinese companies moving stateside.
The Motley Fool April 27, 2010 Brian Orelli	Big Acquisition, Double-Digit Decline. Charles River Labs buys into China big time. But investors would rather have seen it stay home.
The Motley Fool August 13, 2007 Andrew R. Vaino	Do You See What I WuXi? This Chinese biotech outsourcing firm recently went public and has lots of room to grow.
The Motley Fool January 27, 2005 Brian Gorman	Covance's Higher Performance The provider of drug development services' productivity gains and bundled service strategy are driving results.
The Motley Fool October 29, 2009 Robert Steyer	Pharma Researchers Need a Cure As the industry changes, Pharmaceutical Product Development and Parexel International struggle.
The Motley Fool March 6, 2009 Brian Orelli	For Drug Companies, R&D Is Spelled C-R-O It seems likely that more and more pharma companies will try to get more bang for their bucks by spending them on research and development done outside the company, outsourcing it to clinical research organizations.
The Motley Fool August 1, 2008 Brian Orelli	Recession Schmession, This Industry Is On Fire Contract research organizations do pre-clinical research and run clinical trials for drug developers on the cheap. With pharmaceutical companies cutting back on costs, CROs are in the perfect position to benefit.
The Motley Fool April 25, 2005 Brian Gorman	Leaning on a Stronger Covance The drug development services company is helping big pharmaceutical firms. While the company's valuation of 24 times 2005 earnings is a bit a rich, Covance should be on investors' radar.
The Motley Fool May 13, 2008 Brian Orelli	Is Merck Keeping Its Enemies Close? The drugmaker strikes a deal with an Indian generic company.
The Motley Fool January 25, 2007 Brian Gorman	Covance Stays Solid Despite a run-up in the stock, Covance may be in for yet another solid year.
Bio-IT World October 14, 2004 Michael Greeley	Go East Business is great in China, and the government is strongly encouraging the local biotech industry.
The Motley Fool July 30, 2009 Robert Steyer	Covance Advances Covance latest results produce more optimism than did some of its contract research peers.
The Motley Fool June 15, 2006 Brian Gorman	Covance Gets Strategic The drug research service company's latest deal could help it cement its leadership in the industry. Investors, take note.
The Motley Fool January 13, 2011 Brian Orelli	This Trendy Pharma Is Making a Stylish Move Merck signs up a CRO to help with biosimilars.
The Motley Fool July 22, 2004 Brian Gorman	Stability for Covance? After a solid quarter, the drug development service company may have found a way to keep revenue consistent.
The Motley Fool August 3, 2004 Brian Gorman	PAREXEL Gets Leaner The research services provider continues to improve operating performance, but that might not affect its stock price.
The Motley Fool December 27, 2007 Brian Orelli	Drugmaker Growth: The China Connection Just like other industries, the pharmaceutical industry has realized that China is a good place to find cheap labor. While reluctant to set up FDA-regulated manufacturing plants in China, other stages of drug development can be done there.
Pharmaceutical Executive September 1, 2008 Zhu Shen	Unleash the Dragon Concerns over quality? It's not stopping Big Pharma outsourcing and venture capital.
The Motley Fool October 21, 2005 Brian Gorman	Covance Keeps Delivering Investors seemed to fret over the drug-development services company's full-year earnings forecast, but the facts suggest that Covance remains a solid long-term bet.
The Motley Fool January 27, 2006 Brian Gorman	Covance Keeps Humming The provider of drug research services will likely continue to deliver, even if one measure shows signs of tapering off. As a long-term investment, Covance looks like a good bet.
Pharmaceutical Executive May 1, 2005	Thought Leaders: Playing Field in Biotech/Pharma Partnerships Levels As infrastructure and business savvy within biotechs become increasingly sophisticated, the sector's relationship with pharma is taking on a new shape. An interview with industry veteran Lisa Drakeman on how to integrate cultures and processes and where pharma is falling short.
The Motley Fool October 30, 2006 Brian Gorman	Quality in Covance Some investors are pulling back from the company's stock, but Covance will continue to deliver.
The Motley Fool July 12, 2004 Brian Gorman	India Woos U.S. Biotech Companies Business abroad would bode well for investors and consumers.
The Motley Fool April 28, 2006 Brian Gorman	Speed Bumps at Covance Although some problems have cropped up, this drug-research services company is still a solid performer overall. Investors, take note.
The Motley Fool October 3, 2011 Brian D. Pacampara	Pharmaceutical Product Development Shares Soared: What You Need to Know Shares of Pharmaceutical Product Development skyrocketed 25% Monday after The Carlyle Group and Hellman & Friedman LP agreed to buy the health-care research specialist for $3.8 billion.
Pharmaceutical Executive December 1, 2012 Torrey et al.	Transforming Drug Development: A Case Study Eli Lilly's pioneering pact with leading CRO Covance made big news when it happened. Four years later, both parties can point to metrics that suggest the benefit is mutual.
The Motley Fool July 1, 2004 Brian Gorman	Charles River's Big Buy Charles River Laboratories is buying Inveresk Research Group in what appears to be a bid to control more of the burgeoning market for preclinical drug development services.
Commercial Investment Real Estate May/Jun 2011 Anita M. Pittman	Distressed Asset Joint Ventures: A Winning Trifecta? This model can help banks maximize the return on their growing inventory of real estate-owned and troubled loans.
The Motley Fool July 30, 2007 Brian Lawler	AstraZeneca's Yawner of a Quarter The pharma's second-quarter results are ho-hum. Investors may do well to take a look at some of the other big pharma stocks, which offer more compelling reasons to buy.
The Motley Fool October 23, 2009 Robert Steyer	Taking the Drug Industry's Temperature Covance and Icon hint at broader pharmaceutical R&D trends.
The Motley Fool April 20, 2004 Brian Gorman	PPD's New Possibilities The royalty stream from dapoxetine could significantly boost earnings.
The Motley Fool July 22, 2011	Covance Earnings Preview Drug development company Covance beat estimates by $0.02 last quarter, and investors are hoping it can beat them again.
On Wall Street June 1, 2012 Todd Colbeck	The Joint Venture Solution How do you create win/win relationships with other professionals who will go out of their way to refer you to great prospects and future clients?
The Motley Fool October 11, 2007 Billy Fisher	An IPO That Hit the Bull's-Eye Sirtris Pharmaceuticals presents promising drug data and is turning out to be one of the top-performing IPOs in the biotech/pharmaceutical field in 2007.
The Motley Fool March 20, 2006 Brian Gorman	Much Ado About PAREXEL The contract research services provider's shares have been on a roller coaster ride lately, but the ups and downs don't make a lot of sense. Investors, take note.
The Motley Fool December 7, 2010 Michael Kanellos	Suntech Predicts 46 Percent Growth in Shipments in 2011 And a 30 percent growth in revenue with greater margins. Wall Street cautious but optimistic.